Main navigation
- Programs
- Subjects
- Universities
- Destinations
- Advice
Over the last three decades, diabetes cases worldwide have nearly doubled, becoming a primary factor behind vision loss, kidney disease, heart attacks, strokes, and amputations of lower limbs. Existing diabetes treatments remain imperfect, with some causing undesirable side effects. Addressing this urgent need, Ulster's Diabetes Research Group spearheads innovative, globally recognized studies with significant potential for clinical breakthroughs. Their research focuses on four key areas: (1) insulin production and gene-based therapies, (2) diabetes-fighting properties of engineered peptides, (3) identification and effects of anti-diabetic medications, and (4) understanding pancreatic beta-cell malfunctions. This pioneering research has already yielded major scientific findings, generating valuable patents and intellectual assets. Expanding research initiatives provide outstanding interdisciplinary opportunities for new PhD candidates. Notably, Ulster maintains an outstanding reputation for diabetes research training, supported by cutting-edge facilities and specialized knowledge in biochemistry, cellular studies, molecular science, and peptide chemistry.